Legend Biotech will host a conference call on November 12, 2025, to discuss Q3 results and company performance.
Quiver AI Summary
Legend Biotech Corporation will hold a conference call on November 12, 2025, at 8:00 am ET to discuss its third quarter 2025 results. Senior leaders will provide insights into the company's performance, and interested parties can access the call via a live audio webcast. A replay and earnings news release will be available on the company's website shortly after the call. With over 2,800 employees, Legend is a major player in cell therapy, particularly known for its CAR-T cell therapy, CARVYKTI®, developed in partnership with Johnson & Johnson. The company aims to enhance patient access and innovation in cell therapies.
Potential Positives
- Legend Biotech is hosting a conference call to discuss its third quarter 2025 results, demonstrating transparency and engagement with investors.
- The company’s CARVYKTI® is positioned as a leading treatment in the CAR-T cell therapy market for relapsed or refractory multiple myeloma, indicating strong market potential.
- With over 2,800 employees, Legend Biotech emphasizes its status as the largest standalone cell therapy company, reflecting significant growth and organizational strength.
- The focus on expanding patient access and therapeutic potential for CARVYKTI® showcases the company's commitment to innovation and leadership in cell therapy.
Potential Negatives
- There is no specific mention of financial performance or growth metrics in the press release, which could raise concerns among investors regarding the company's current financial health.
- The press release does not provide any details about potential challenges or risks the company is facing, potentially leaving investors unsure about the company's stability.
- By focusing solely on an upcoming conference call without delivering immediate results or insights, the company may be viewed as lacking transparency or initiative in addressing investor concerns promptly.
FAQ
When will Legend Biotech host its conference call for Q3 2025 results?
Legend Biotech will host the conference call on Wednesday, November 12, 2025, at 8:00 am ET.
How can investors participate in the Legend Biotech conference call?
Investors can join the conference call via the live audio webcast available on Legend Biotech's website.
What is CARVYKTI® and its significance?
CARVYKTI® is a one-time CAR-T cell therapy for relapsed or refractory multiple myeloma, developed in partnership with Johnson & Johnson.
Where can I find the replay of the conference call?
A replay of the conference call will be available in the Investor Relations section of Legend Biotech’s website approximately two hours post-call.
How many employees does Legend Biotech have?
Legend Biotech employs over 2,800 people and is a leader in the cell therapy industry.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LEGN Hedge Fund Activity
We have seen 106 institutional investors add shares of $LEGN stock to their portfolio, and 110 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 12,466,098 shares (+94.4%) to their portfolio in Q2 2025, for an estimated $442,421,818
- PRICE T ROWE ASSOCIATES INC /MD/ removed 5,929,559 shares (-88.1%) from their portfolio in Q2 2025, for an estimated $210,440,048
- DEERFIELD MANAGEMENT COMPANY, L.P. added 2,962,338 shares (+inf%) to their portfolio in Q2 2025, for an estimated $105,133,375
- INVESCO LTD. removed 2,919,873 shares (-99.4%) from their portfolio in Q2 2025, for an estimated $103,626,292
- WELLINGTON MANAGEMENT GROUP LLP removed 1,857,268 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $65,914,441
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 1,824,735 shares (-80.4%) from their portfolio in Q2 2025, for an estimated $64,759,845
- ARTISAN PARTNERS LIMITED PARTNERSHIP added 990,500 shares (+87.5%) to their portfolio in Q2 2025, for an estimated $35,152,845
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LEGN Analyst Ratings
Wall Street analysts have issued reports on $LEGN in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/17/2025
- Cantor Fitzgerald issued a "Overweight" rating on 08/27/2025
- RBC Capital issued a "Outperform" rating on 08/12/2025
- Morgan Stanley issued a "Overweight" rating on 08/12/2025
- UBS issued a "Buy" rating on 07/02/2025
- Truist Securities issued a "Buy" rating on 05/14/2025
To track analyst ratings and price targets for $LEGN, check out Quiver Quantitative's $LEGN forecast page.
$LEGN Price Targets
Multiple analysts have issued price targets for $LEGN recently. We have seen 9 analysts offer price targets for $LEGN in the last 6 months, with a median target of $71.0.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $60.0 on 10/17/2025
- Jessica Fye from JP Morgan set a target price of $76.0 on 10/09/2025
- Eric Schmidt from Cantor Fitzgerald set a target price of $66.0 on 08/27/2025
- Matthew Harrison from Morgan Stanley set a target price of $83.0 on 08/12/2025
- Leonid Timashev from RBC Capital set a target price of $77.0 on 08/12/2025
- Ashwani Verma from UBS set a target price of $54.0 on 07/02/2025
- Asthika Goonewardene from Truist Securities set a target price of $71.0 on 05/14/2025
Full Release
SOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Wednesday, November 12, 2025, to review third quarter 2025 results.
During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter.
Investors and other interested parties may join the live audio webcast of the call via this weblink.
A replay of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech’s website under the Events and Presentations section approximately two hours after the call concludes.
ABOUT LEGEND BIOTECH
With over 2,800 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI ® , a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more at www.legendbiotech.com , and follow us on LinkedIn .
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
[email protected]
PRESS CONTACT:
Alexandra Ventura
Tel: (732) 850-5598
[email protected]
